Conference Track

Lung Cancer

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Clinical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Bevacizumab Added to First-Line Paclitaxel/Carboplatin Improves Response and Survival in Patients With Advanced Nonsquamous NSCLC
Addition of Bexarotene to Carboplatin/Paclitaxel Chemotherapy Does Not Improve Survival for Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer
Tumor ERCC1 Levels Correlate With Response to Cisplatin Therapy in Patients With Advanced NSCLC
Oral Topotecan Plus Cisplatin as Tolerable and Efficacious as Standard Etoposide Plus Cisplatin in Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer
Irinotecan/Cisplatin Effective for Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
EGFR Mutations Associated With Improved Outcomes in Patients With Advanced NSCLC Treated With Gefitinib
EGFR Mutations Do Not Predict Response to Erlotinib in Patients With NSCLC
Significantly Improved Response to Gefitinib in Patients With EGFR Mutations Without K-ras Mutation
Paclitaxel Poliglumex/Carboplatin Well Tolerated and Provides Survival Benefit Similar to Paclitaxel/Carboplatin as First-Line Treatment In Non-Small-Cell Lung Carcinoma
Docetaxel Treatment Prolongs Survival and Response Rate Compared With Vinorelbine in Elderly Patients With Non-Small-Cell Lung Cancer
Preoperative Paclitaxel/Carboplatin Improves Survival in Resectable NSCLC
Adjuvant Vinorelbine/Cisplatin Improves Survival in Completely Resected Early Stage NSCLC
Surgical Resection Offers No Benefit Over Thoracic Radiotherapy After Induction Chemotherapy in Late-Stage Non-Small-Cell Lung Cancer
Bexarotene Plus Cisplatin/Vinorelbine Chemotherapy Does Not Improve Survival in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer
Improved Long-Term Survival in Patients With Stage 3b Non-Small-Cell Lung Cancer Treated With Concurrent Cisplatin/Etoposide and Thoracic Radiotherapy Followed by Consolidation Docetaxel
Single-Agent Chemotherapy Confers a Survival Benefit in Elderly Patients With Non-small Cell Lung Cancer
Weekly Docetaxel With and Without Gemcitabine Well Tolerated in Poor Prognosis Elderly Patients With NSCLC
SWOG 0023: Maintenance Gefitinib Does Not Improve Survival in Unresectable Stage 3 NSCLC

Expert Analysis

Lung Cancer

Program Director:
Roy A. Beveridge, MD

Faculty:
Paul A. Bunn, Jr., MD Thomas J. Lynch, MD David S. Ettinger, MD
David R. Gandara, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recall new treatment strategies under investigation for small-cell lung cancer
Recount recent analyses of gene mutations and protein expression in patients with non-small-cell lung cancer treated with targeted therapies
Describe findings from clinical investigations of preoperative or adjuvant chemotherapy in non-small-cell lung cancer
List recent treatment strategies involving combination chemotherapy or targeted therapy in advanced non-small-cell lung cancer

Earn CME credit by reading the expert analysis and commentary on lung cancer. Topics covered include:

Biomarkers for Treatment Response: Erlotinib in NSCLC
Biomarkers for Treatment Response: Gefitinib in NSCLC
Biomarkers for Treatment Response: Gefitinib in Bronchioalveolar Carcinoma
Early-Stage NSCLC: Preoperative Carboplatin/Paclitaxel
Early-Stage NSCLC: Adjuvant Vinorelbine/Cisplatin
Stage IIIA-N2 NSCLC: Surgery vs Thoracic Radiotherapy, EORTC 08941
Stage IIIA (pN2) NSCLC: Surgery vs Thoracic Radiotherapy in INT 0139
Chemoradiation in Stage III NSCLC: SWOG Trials
Bevacizumab in Advanced NSCLC: ECOG E4599
Bexarotene in Advanced NSCLC: SPIRIT 1 and 2
Paclitaxel Poliglumex in PS 2 NSCLC: STELLAR 3
Treatment of Elderly Patients with NSCLC
Treatment of SCLC: Oral Topotecan
Treatment of SCLC: Irinotecan

CME CREDIT INFORMATION

Release Date: 07/21/05

Expiration Date: 07/20/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.8 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.